Skip to main content

Alpha 1-Antitrypsin Deficiency clinical trials at UCSD

2 in progress, 1 open to eligible people

Showing trials for
  • Alpha-1 Antitrypsin Deficiency Adult Liver Study

    open to eligible people ages 18 years and up

    The investigators hypothesize that there is liver injury (inflammation, fibrosis, cirrhosis) in adults with Alpha-1 Antitrypsin Deficiency (AATD), which is asymptomatic, under-recognized, and undiagnosed. In addition, the investigators believe that the genetic and environmental factors that play an important role in the development of alpha-1 antitrypsin (AAT) liver disease, can be identified by comparing a cohort database of clinical disease information to linked biospecimen and DNA samples.

    San Diego, California and other locations

  • Safety, Tolerability and Pharmacodynamic Effect of ARO-AAT

    Sorry, in progress, not accepting new patients

    The purpose of AROAAT2001 (SEQUOIA) is to evaluate the safety, efficacy and tolerability of multiple doses of the investigational product, ARO-AAT, administered subcutaneously to participants with alpha-1 antitrypsin deficiency (AATD).

    La Jolla, California and other locations

Last updated: